Study of YKST02 for multiple myeloma that has come back or not responded
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an investigational drug called YKST02 for people with multiple myeloma that has returned or not improved after at least two prior treatments. The goal is to see if YKST02 can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or not responded to at least two prior lines of therapy.
- You have received a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody in the past.
- You are well enough to care for yourself (ECOG performance status 0 or 1) and expected to live at least 12 weeks.
- Your blood counts, liver, kidney, and clotting function meet study standards.
- You have not had certain prior treatments, including BCMA-targeted therapy or CAR T-cell therapy.
- You are willing to use effective contraception during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called YKST02 for people with multiple myeloma that has come back or hasn't responded to other treatments. The goal is to see if it can help when other therapies have stopped working.
This trial tests an anti-CD38 antibody drug that is “linked” to a cancer-killing payload (an antibody-drug conjugate) in people with multiple myeloma that has returned or did not respond to standard treatments. It is mainly looking at safety first, and also whether it can reduce myeloma in heavily pre-treated patients.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new drug called QI-019B for people with multiple myeloma whose cancer has come back or stopped responding to other treatments. The goal is to see if it is safe and can help shrink or slow the cancer.
This trial tests a new drug, SHR-5421, for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
This trial tests a new cell therapy (KSVCBD) for people with multiple myeloma that has returned or not responded to other treatments. It may help if your cancer cells have certain markers, CD19 or BCMA.
Hear when a new Relapsed or Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.